Diastolic Heart Failure – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Diastolic Heart Failure (HFpEF) – Drugs In Development, 2024 report and make more profitable business decisions.
Diastolic heart failure, also known as heart failure with preserved ejection fraction, is a condition in which the heart’s main pumping chamber becomes stiff and unable to fill properly. One of the two types of left-sided heart failure is diastolic heart failure. Main causes include high blood pressure, diabetes, coronary artery disease, and obesity. Untreated diastolic heart failure has the potential to be fatal.
The Diastolic Heart Failure (HFpEF) drugs in development market research report provide comprehensive information on the therapeutics under development for Diastolic Heart Failure (HFpEF), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diastolic Heart Failure (HFpEF) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Diastolic Heart Failure (HFpEF) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 45 molecules, with 44 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Diastolic Heart Failure (HFpEF) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Diastolic Heart Failure (HFpEF) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Diastolic Heart Failure (HFpEF) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Adicet Bio IncAkebia Therapeutics Inc
Amplifier TX AB
AstraZeneca Plc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
C&C BioPharma LLC
Cardiol Therapeutics Inc
Cardurion Pharmaceuticals LLC
Cytokinetics Inc
DiNAQOR AG
Edgewise Therapeutics Inc
Eli Lilly and Co
Gatehouse Bio
I-Cordis LLC
Imbria Pharmaceuticals Inc
Johnson & Johnson
Keros Therapeutics Inc
Mitsubishi Tanabe Pharma Corp
Nagoya University
Novartis AG
Novo Nordisk AS
Organicell Regenerative Medicine Inc
Palatin Technologies Inc
Pfizer Inc
Poxel SA
River BioMedics BV
Rivus Pharmaceuticals Inc
Salubris Biotherapeutics Inc
Sardocor Corp
Sarfez Pharmaceuticals Inc
Selah Therapeutics Ltd
Signal Pharma Ltd
Tenax Therapeutics Inc
Tenaya Therapeutics Inc
Vasa Therapeutics SP Zoo
Versanis Bio Inc
Zensun (Shanghai) Sci & Tech Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Diastolic Heart Failure reports